Literature DB >> 12359367

Expression of cysteine peptidase cathepsin L and its inhibitors stefins A and B in relation to tumorigenicity of breast cancer cell lines.

Irena Zajc1, Natasa Sever, Ales Bervar, Tamara T Lah.   

Abstract

The in vitro invasiveness of human breast cancer cell lines was compared with their reported tumorigenicity in vivo, increasing from MCF7, MDA-MB468, MDA-MB231 to MDA-MB435 cells. The invasiveness roughly corresponded to the tumorigenicity of the cell lines. The levels of cathepsin L mRNA and protein correlated with the invasiveness of the cells. Stefin A protein decreased with the invasiveness and the reported tumorigenicity, whereas stefin B protein was significantly lower in all MDA-MB lines compared with the least invasive and tumorigenic MCF7 line. Our results suggest that the imbalance between cathepsin L and the stefins contributes to the development of a malignant cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12359367     DOI: 10.1016/s0304-3835(02)00452-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

Review 1.  Cathepsin L targeting in cancer treatment.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Pharmacol Ther       Date:  2015-08-20       Impact factor: 12.310

2.  Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer.

Authors:  T Leinonen; R Pirinen; J Böhm; R Johansson; A Rinne; E Weber; V-M Kosma
Journal:  J Clin Pathol       Date:  2006-06-21       Impact factor: 3.411

3.  Functional expression of recombinant human stefin A in mammalian and bacterial cells.

Authors:  Catharine C Calkins; Julie Dosescu; Nancy A Day; Wei-Ping Ren; Rafael Fridman; Bonnie F Sloane; Kamiar Moin
Journal:  Protein Expr Purif       Date:  2006-12-09       Impact factor: 1.650

4.  Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.

Authors:  Erica N Parker; Jiangli Song; G D Kishore Kumar; Samuel O Odutola; Gustavo E Chavarria; Amanda K Charlton-Sevcik; Tracy E Strecker; Ashleigh L Barnes; Dhivya R Sudhan; Thomas R Wittenborn; Dietmar W Siemann; Michael R Horsman; David J Chaplin; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2015-09-25       Impact factor: 3.641

Review 5.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

Review 6.  Modulation of the tumor vasculature and oxygenation to improve therapy.

Authors:  Dietmar W Siemann; Michael R Horsman
Journal:  Pharmacol Ther       Date:  2015-06-11       Impact factor: 12.310

7.  Cathepsin L inhibition by the small molecule KGP94 suppresses tumor microenvironment enhanced metastasis associated cell functions of prostate and breast cancer cells.

Authors:  Dhivya R Sudhan; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2013-06-09       Impact factor: 5.150

8.  Stress-resistant Translation of Cathepsin L mRNA in Breast Cancer Progression.

Authors:  Martina Tholen; Julia Wolanski; Britta Stolze; Marco Chiabudini; Mieczyslaw Gajda; Peter Bronsert; Elmar Stickeler; Sabine Rospert; Thomas Reinheckel
Journal:  J Biol Chem       Date:  2015-05-08       Impact factor: 5.157

9.  Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment.

Authors:  Ghada Abboud-Jarrous; Ruth Atzmon; Tamar Peretz; Carmela Palermo; Bedrick B Gadea; Johanna A Joyce; Israel Vlodavsky
Journal:  J Biol Chem       Date:  2008-04-30       Impact factor: 5.157

10.  Three-dimensional cultures modeling premalignant progression of human breast epithelial cells: role of cysteine cathepsins.

Authors:  Stefanie R Mullins; Mansoureth Sameni; Galia Blum; Matthew Bogyo; Bonnie F Sloane; Kamiar Moin
Journal:  Biol Chem       Date:  2012-12       Impact factor: 3.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.